4171 Stock Overview
Develops, manufactures, and markets products for applied nucleic acid detection technology in Taiwan. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
GeneReach Biotechnology Corp. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | NT$27.00 |
| 52 Week High | NT$42.80 |
| 52 Week Low | NT$25.40 |
| Beta | 0.83 |
| 1 Month Change | -6.90% |
| 3 Month Change | -14.56% |
| 1 Year Change | -31.82% |
| 3 Year Change | -57.18% |
| 5 Year Change | -43.38% |
| Change since IPO | -9.00% |
Recent News & Updates
Recent updates
Does GeneReach Biotechnology (GTSM:4171) Have A Healthy Balance Sheet?
Apr 18
Will Weakness in GeneReach Biotechnology Corp.'s (GTSM:4171) Stock Prove Temporary Given Strong Fundamentals?
Feb 28We Like GeneReach Biotechnology's (GTSM:4171) Returns And Here's How They're Trending
Jan 31The GeneReach Biotechnology (GTSM:4171) Share Price Is Up 596% And Shareholders Are Delighted
Dec 27
GeneReach Biotechnology Corp.'s (GTSM:4171) Fundamentals Look Pretty Strong: Could The Market Be Wrong About The Stock?
Nov 28Shareholder Returns
| 4171 | TW Medical Equipment | TW Market | |
|---|---|---|---|
| 7D | 1.1% | 2.1% | 0.5% |
| 1Y | -31.8% | -4.7% | 27.8% |
Return vs Industry: 4171 underperformed the TW Medical Equipment industry which returned -4.7% over the past year.
Return vs Market: 4171 underperformed the TW Market which returned 27.8% over the past year.
Price Volatility
| 4171 volatility | |
|---|---|
| 4171 Average Weekly Movement | 2.9% |
| Medical Equipment Industry Average Movement | 3.8% |
| Market Average Movement | 4.4% |
| 10% most volatile stocks in TW Market | 7.8% |
| 10% least volatile stocks in TW Market | 2.1% |
Stable Share Price: 4171 has not had significant price volatility in the past 3 months compared to the TW market.
Volatility Over Time: 4171's weekly volatility (3%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2004 | n/a | n/a | www.genereach.com |
GeneReach Biotechnology Corp. develops, manufactures, and markets products for applied nucleic acid detection technology in Taiwan. The company offers automatic nucleic acid extraction systems, prep homogenization system, and mini centrifuge equipment; and reagents and consumables, comprising human IVD assays, iiPCR specific reagents, taco nucleic acid extraction reagents, IQ real quantitative systems, IQ2000 detection and prevention systems, and research reagents and consumables. The company also provides polymerase chain reaction training programs, molecular diagnostic technical solutions, laboratory installation services, OEM/ODM contract manufacturing services, and research collaboration services.
GeneReach Biotechnology Corp. Fundamentals Summary
| 4171 fundamental statistics | |
|---|---|
| Market cap | NT$1.55b |
| Earnings (TTM) | -NT$141.55m |
| Revenue (TTM) | NT$206.35m |
7.5x
P/S Ratio-11.0x
P/E RatioIs 4171 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 4171 income statement (TTM) | |
|---|---|
| Revenue | NT$206.35m |
| Cost of Revenue | NT$140.66m |
| Gross Profit | NT$65.69m |
| Other Expenses | NT$207.24m |
| Earnings | -NT$141.55m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.46 |
| Gross Margin | 31.83% |
| Net Profit Margin | -68.60% |
| Debt/Equity Ratio | 22.9% |
How did 4171 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/25 20:17 |
| End of Day Share Price | 2024/12/25 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
GeneReach Biotechnology Corp. is covered by 3 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Zhennan Lee | Jih Sun Securities Investment Consulting Co., Ltd. |
| Hsiu Chi Lin | Masterlink Securities Corp. |
| Yijun Chen | SinoPac Securities Investment Service |